Product logins

Find logins to all Clarivate products below.


We review the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on MCI.

We summarize the results of our review for the epidemiological estimates of prevalence that are used directly in our forecast model in the “Studies Included” table. How we used these estimates and to which countries they were applied are discussed in the text and summarized in the sources table in the relevant epidemiology population sections. We report the most relevant sources not used and the reason for not using them in the “Studies Excluded” table

Related Market Assessment Reports

Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Multiple Sclerosis – Landscape & Forecast – Disease Landscape & Forecast (G7)
The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s Kisunla (donanemab) have launched for the treatment of early Alzheimer’s disease (AD) in the United States and Japan and, after early…
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
Report
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of CIDP comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…